CNS Lymphoma Market- Industry Analysis, Growth, Segmentation Market Size by End-Use, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2019

N/A
CAGR (2020-2026)
N/A
Market Size
311
Report Pages
138
Market Tables

Overview

Global CNS Lymphoma Market was valued $xx Mn in 2019 and is expected to reach $xx Mn by 2026, at a CAGR of xx%.

Global CNS Lymphoma Market: Introduction

Central nervous system lymphoma is an extra nodal non-Hodgkin lymphoma (NHL) that is confined to the brain, leptomeninges, eyes, or spinal cord. CNS lymphoma is a rare malignancy, comprising only 2% of primary CNS tumours in the United States. The annual incidence of primary CNS lymphoma in the United States is approximately 1,400 cases; this is steadily increasing as the population ages. A similarly higher incidence is seen in Caucasians compared with African Americans. The incidence in Hispanics appears to be similar to that in non-Hispanics.

Global CNS Lymphoma: Market Dynamics

The past decade has witnessed an acceleration in progress in central nervous system (CNS) lymphoma research. Key insights were made into its molecular pathophysiology, yielding advances in molecular and genetic diagnosis, prognostication, and implementation of innovative experimental approaches. Anti-CD20 antibody–based immunotherapy has become a cornerstone of treatment. The market is expected to be majorly driven by the rising prevalence of primary CNS lymphoma, increasing awareness regarding the advanced technologies in the market, and rising governmental spending on healthcare. The demand for diagnostic methods is on the surge; thus, propelling the demand for CNS lymphoma treatment across the regions.

Global CNS Lymphoma Market: Segment Analysis

By treatment segment is expected to drive the CNS Lymphoma Market

The treatment segment is expected to grow at a CAGR of xx% during the forecast period. The increasing incidences of lymphoma are driving the market growth. Chemotherapy plays the most important role in the treatment of PCNSL. MTX, the most widely used drug for PCNSL, is a folate antagonist that interrupts DNA synthesis.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Because primary CNS lymphoma spreads throughout the brain, external radiation therapy is given to the whole brain. RT covering both the whole brain and posterior orbits, termed whole-brain radiotherapy (WBRT), is the most frequently utilized approach because of the potential for out-of-field failures. Current research is focusing on reducing the risk of neurotoxicity from RT without compromising long-term disease control.

Hospital segment expected to grow at a faster pace owing to the increased treatment processes.

By end-use, the hospital segment is expected to register a CAGR of xx% during the forecast period. Hospitals held a leading revenue share of xx% in the Lymphoma Market in 2020. Surgeries and other operations are performed majorly in hospitals, due to availability of all tools and technologies required. Treatment procedures conducted in hospitals or hospital-attached outpatient facilities enable ease of handling any emergency situations that may arise.

Global CNS Lymphoma Market

To Know About The Research Methodology :- Request Free Sample Report

Global CNS Lymphoma Market: Regional Analysis

 

Global CNS Lymphoma Market1

North America accounted for the largest share of xx% in 2019, reason being the rising prevalence of cancer associated lymphedema. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field has boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market.

Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected drive the market demand.

Scope of Report Global CNS Lymphoma Market:  Inquire before buying

Global CNS Lymphoma Market2

Global CNS Lymphoma Market: By Region

• North America
• Europe
• South America
• MEA
• Asia Pacific

Global CNS Lymphoma Market: Key Players

• Amgen
• Dr. Reddy’s Laboratories
• Roche
• Bristol-Myers Squibb
• Cipla
• Merck
• Gilead Science
• Novartis
• AbbVie
• Fresenius SE & Co
• KGaA
• Sanofi S.A
• Celgene Corp
• Johnson & Johnson

Recent Development:

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, has announced that it hasentered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to investigate the use of Kazia's investigational new drug, paxalisib (formerly GDC-0084), in primary central nervous system (CNS) lymphoma, a potential new indication for the drug.

Table of Contents

Global CNS Lymphoma Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: CNS Lymphoma Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global CNS Lymphoma Market Analysis and Forecast 6.1. CNS Lymphoma Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global CNS Lymphoma Market Analysis and Forecast, By Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. CNS Lymphoma Market Value Share Analysis, By Treatment 7.4. CNS Lymphoma Market Size (US$ Mn) Forecast, By Treatment 7.5. CNS Lymphoma Market Analysis, By Treatment 7.6. CNS Lymphoma Market Attractiveness Analysis, By Treatment 8. Global CNS Lymphoma Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. CNS Lymphoma Market Value Share Analysis, By Application 8.4. CNS Lymphoma Market Size (US$ Mn) Forecast, By Application 8.5. CNS Lymphoma Market Analysis, By Application 8.6. CNS Lymphoma Market Attractiveness Analysis, By Application 9. Global CNS Lymphoma Market Analysis, By Region 9.1. CNS Lymphoma Market Value Share Analysis, By Region 9.2. CNS Lymphoma Market Size (US$ Mn) Forecast, By Region 9.3. CNS Lymphoma Market Attractiveness Analysis, By Region 10. North America CNS Lymphoma Market Analysis 10.1. Key Findings 10.2. North America CNS Lymphoma Market Overview 10.3. North America CNS Lymphoma Market Value Share Analysis, By Treatment 10.4. North America CNS Lymphoma Market Forecast, By Treatment 10.4.1. Chemotherapy 10.4.2. Radiation Therapy 10.4.3. Steroid Therapy 10.4.4. Targeted Therapy 10.5. North America CNS Lymphoma Market Value Share Analysis, By Application 10.6. North America CNS Lymphoma Market Forecast, By Application 10.6.1. Hospitals 10.6.2. Clinics 10.6.3. Ambulatory Surgical Centers and Others 10.7. North America CNS Lymphoma Market Value Share Analysis, By Country 10.8. North America CNS Lymphoma Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America CNS Lymphoma Market Analysis, By Country 10.10. U.S. CNS Lymphoma Market Forecast, By Treatment 10.10.1. Chemotherapy 10.10.2. Radiation Therapy 10.10.3. Steroid Therapy 10.10.4. Targeted Therapy 10.11. U.S. CNS Lymphoma Market Forecast, By Application 10.11.1. Hospitals 10.11.2. Clinics 10.11.3. Ambulatory Surgical Centers and Others 10.12. Canada CNS Lymphoma Market Forecast, By Treatment 10.12.1. Chemotherapy 10.12.2. Radiation Therapy 10.12.3. Steroid Therapy 10.12.4. Targeted Therapy 10.13. Canada CNS Lymphoma Market Forecast, By Application 10.13.1. Hospitals 10.13.2. Clinics 10.13.3. Ambulatory Surgical Centers and Others 10.14. Mexico CNS Lymphoma Market Forecast, By Treatment 10.14.1. Chemotherapy 10.14.2. Radiation Therapy 10.14.3. Steroid Therapy 10.14.4. Targeted Therapy 10.15. Mexico CNS Lymphoma Market Forecast, By Application 10.15.1. Hospitals 10.15.2. Clinics 10.15.3. Ambulatory Surgical Centers and Others 10.16. North America CNS Lymphoma Market Attractiveness Analysis 10.16.1. By Treatment 10.16.2. By Application 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe CNS Lymphoma Market Analysis 11.1. Key Findings 11.2. Europe CNS Lymphoma Market Overview 11.3. Europe CNS Lymphoma Market Value Share Analysis, By Treatment 11.4. Europe CNS Lymphoma Market Forecast, By Treatment 11.4.1. Chemotherapy 11.4.2. Radiation Therapy 11.4.3. Steroid Therapy 11.4.4. Targeted Therapy 11.5. Europe CNS Lymphoma Market Value Share Analysis, By Application 11.6. Europe CNS Lymphoma Market Forecast, By Application 11.6.1. Hospitals 11.6.2. Clinics 11.6.3. Ambulatory Surgical Centers and Others 11.7. Europe CNS Lymphoma Market Value Share Analysis, By Country 11.8. Europe CNS Lymphoma Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany CNS Lymphoma Market Forecast, By Treatment 11.9.1. Chemotherapy 11.9.2. Radiation Therapy 11.9.3. Steroid Therapy 11.9.4. Targeted Therapy 11.10. Germany CNS Lymphoma Market Forecast, By Application 11.10.1. Hospitals 11.10.2. Clinics 11.10.3. Ambulatory Surgical Centers and Others 11.11. U.K. CNS Lymphoma Market Forecast, By Treatment 11.11.1. Chemotherapy 11.11.2. Radiation Therapy 11.11.3. Steroid Therapy 11.11.4. Targeted Therapy 11.12. U.K. CNS Lymphoma Market Forecast, By Application 11.12.1. Hospitals 11.12.2. Clinics 11.12.3. Ambulatory Surgical Centers and Others 11.13. France CNS Lymphoma Market Forecast, By Treatment 11.13.1. Chemotherapy 11.13.2. Radiation Therapy 11.13.3. Steroid Therapy 11.13.4. Targeted Therapy 11.14. France CNS Lymphoma Market Forecast, By Application 11.14.1. Hospitals 11.14.2. Clinics 11.14.3. Ambulatory Surgical Centers and Others 11.15. Italy CNS Lymphoma Market Forecast, By Treatment 11.15.1. Chemotherapy 11.15.2. Radiation Therapy 11.15.3. Steroid Therapy 11.15.4. Targeted Therapy 11.16. Italy CNS Lymphoma Market Forecast, By Application 11.16.1. Hospitals 11.16.2. Clinics 11.16.3. Ambulatory Surgical Centers and Others 11.17. Spain CNS Lymphoma Market Forecast, By Treatment 11.17.1. Chemotherapy 11.17.2. Radiation Therapy 11.17.3. Steroid Therapy 11.17.4. Targeted Therapy 11.18. Spain CNS Lymphoma Market Forecast, By Application 11.18.1. Hospitals 11.18.2. Clinics 11.18.3. Ambulatory Surgical Centers and Others 11.19. Sweden CNS Lymphoma Market Forecast, By Treatment 11.19.1. Chemotherapy 11.19.2. Radiation Therapy 11.19.3. Steroid Therapy 11.19.4. Targeted Therapy 11.20. Sweden CNS Lymphoma Market Forecast, By Application 11.20.1. Hospitals 11.20.2. Clinics 11.20.3. Ambulatory Surgical Centers and Others 11.21. CIS countries CNS Lymphoma Market Forecast, By Treatment 11.21.1. Chemotherapy 11.21.2. Radiation Therapy 11.21.3. Steroid Therapy 11.21.4. Targeted Therapy 11.22. CIS countries CNS Lymphoma Market Forecast, By Application 11.22.1. Hospitals 11.22.2. Clinics 11.22.3. Ambulatory Surgical Centers and Others 11.23. Rest of Europe CNS Lymphoma Market Forecast, By Treatment 11.23.1. Chemotherapy 11.23.2. Radiation Therapy 11.23.3. Steroid Therapy 11.23.4. Targeted Therapy 11.24. Rest of Europe CNS Lymphoma Market Forecast, By Application 11.24.1. Hospitals 11.24.2. Clinics 11.24.3. Ambulatory Surgical Centers and Others 11.25. Europe CNS Lymphoma Market Attractiveness Analysis 11.25.1. By Application 11.25.2. By Treatment 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific CNS Lymphoma Market Analysis 12.1. Key Findings 12.2. Asia Pacific CNS Lymphoma Market Overview 12.3. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Treatment 12.4. Asia Pacific CNS Lymphoma Market Forecast, By Treatment 12.4.1. Chemotherapy 12.4.2. Radiation Therapy 12.4.3. Steroid Therapy 12.4.4. Targeted Therapy 12.5. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Application 12.6. Asia Pacific CNS Lymphoma Market Forecast, By Application 12.6.1. Hospitals 12.6.2. Clinics 12.6.3. Ambulatory Surgical Centers and Others 12.7. Asia Pacific CNS Lymphoma Market Value Share Analysis, By Country 12.8. Asia Pacific CNS Lymphoma Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific CNS Lymphoma Market Analysis, By Country 12.10. China CNS Lymphoma Market Forecast, By Treatment 12.10.1. Chemotherapy 12.10.2. Radiation Therapy 12.10.3. Steroid Therapy 12.10.4. Targeted Therapy 12.11. China CNS Lymphoma Market Forecast, By Application 12.11.1. Hospitals 12.11.2. Clinics 12.11.3. Ambulatory Surgical Centers and Others 12.12. India CNS Lymphoma Market Forecast, By Treatment 12.12.1. Chemotherapy 12.12.2. Radiation Therapy 12.12.3. Steroid Therapy 12.12.4. Targeted Therapy 12.13. India CNS Lymphoma Market Forecast, By Application 12.13.1. Hospitals 12.13.2. Clinics 12.13.3. Ambulatory Surgical Centers and Others 12.14. Japan CNS Lymphoma Market Forecast, By Treatment 12.14.1. Chemotherapy 12.14.2. Radiation Therapy 12.14.3. Steroid Therapy 12.14.4. Targeted Therapy 12.15. Japan CNS Lymphoma Market Forecast, By Application 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Ambulatory Surgical Centers and Others 12.16. South Korea CNS Lymphoma Market Forecast, By Treatment 12.16.1. Chemotherapy 12.16.2. Radiation Therapy 12.16.3. Steroid Therapy 12.16.4. Targeted Therapy 12.17. South Korea CNS Lymphoma Market Forecast, By Application 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Ambulatory Surgical Centers and Others 12.18. Australia CNS Lymphoma Market Forecast, By Treatment 12.18.1. Chemotherapy 12.18.2. Radiation Therapy 12.18.3. Steroid Therapy 12.18.4. Targeted Therapy 12.19. Australia CNS Lymphoma Market Forecast, By Application 12.19.1. Hospitals 12.19.2. Clinics 12.19.3. Ambulatory Surgical Centers and Others 12.20. ASEAN CNS Lymphoma Market Forecast, By Treatment 12.20.1. Chemotherapy 12.20.2. Radiation Therapy 12.20.3. Steroid Therapy 12.20.4. Targeted Therapy 12.21. ASEAN CNS Lymphoma Market Forecast, By Application 12.21.1. Hospitals 12.21.2. Clinics 12.21.3. Ambulatory Surgical Centers and Others 12.22. Rest of Asia Pacific CNS Lymphoma Market Forecast, By Treatment 12.22.1. Chemotherapy 12.22.2. Radiation Therapy 12.22.3. Steroid Therapy 12.22.4. Targeted Therapy 12.23. Rest of Asia Pacific CNS Lymphoma Market Forecast, By Application 12.23.1. Hospitals 12.23.2. Clinics 12.23.3. Ambulatory Surgical Centers and Others 12.24. Asia Pacific CNS Lymphoma Market Attractiveness Analysis 12.24.1. By Treatment 12.24.2. By Application 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa CNS Lymphoma Market Analysis 13.1. Key Findings 13.2. Middle East & Africa CNS Lymphoma Market Overview 13.3. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Treatment 13.4. Middle East & Africa CNS Lymphoma Market Forecast, By Treatment 13.4.1. Chemotherapy 13.4.2. Radiation Therapy 13.4.3. Steroid Therapy 13.4.4. Targeted Therapy 13.5. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Application 13.6. Middle East & Africa CNS Lymphoma Market Forecast, By Application 13.6.1. Hospitals 13.6.2. Clinics 13.6.3. Ambulatory Surgical Centers and Others 13.7. Middle East & Africa CNS Lymphoma Market Value Share Analysis, By Country 13.8. Middle East & Africa CNS Lymphoma Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa CNS Lymphoma Market Analysis, By Country 13.10. GCC Countries CNS Lymphoma Market Forecast, By Treatment 13.10.1. Chemotherapy 13.10.2. Radiation Therapy 13.10.3. Steroid Therapy 13.10.4. Targeted Therapy 13.11. GCC Countries CNS Lymphoma Market Forecast, By Application 13.11.1. Hospitals 13.11.2. Clinics 13.11.3. Ambulatory Surgical Centers and Others 13.12. South Africa CNS Lymphoma Market Forecast, By Treatment 13.12.1. Chemotherapy 13.12.2. Radiation Therapy 13.12.3. Steroid Therapy 13.12.4. Targeted Therapy 13.13. South Africa CNS Lymphoma Market Forecast, By Application 13.13.1. Hospitals 13.13.2. Clinics 13.13.3. Ambulatory Surgical Centers and Others 13.14. Nigeria CNS Lymphoma Market Forecast, By Treatment 13.14.1. Chemotherapy 13.14.2. Radiation Therapy 13.14.3. Steroid Therapy 13.14.4. Targeted Therapy 13.15. Nigeria CNS Lymphoma Market Forecast, By Application 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Ambulatory Surgical Centers and Others 13.16. Egypt CNS Lymphoma Market Forecast, By Treatment 13.16.1. Chemotherapy 13.16.2. Radiation Therapy 13.16.3. Steroid Therapy 13.16.4. Targeted Therapy 13.17. Egypt CNS Lymphoma Market Forecast, By Application 13.17.1. Hospitals 13.17.2. Clinics 13.17.3. Ambulatory Surgical Centers and Others 13.18. Rest of Middle East & Africa CNS Lymphoma Market Forecast, By Treatment 13.18.1. Chemotherapy 13.18.2. Radiation Therapy 13.18.3. Steroid Therapy 13.18.4. Targeted Therapy 13.19. Rest of Middle East & Africa CNS Lymphoma Market Forecast, By Application 13.19.1. Hospitals 13.19.2. Clinics 13.19.3. Ambulatory Surgical Centers and Others 13.20. Middle East & Africa CNS Lymphoma Market Attractiveness Analysis 13.20.1. By Treatment 13.20.2. By Application 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America CNS Lymphoma Market Analysis 14.1. Key Findings 14.2. South America CNS Lymphoma Market Overview 14.3. South America CNS Lymphoma Market Value Share Analysis, By Treatment 14.4. South America CNS Lymphoma Market Forecast, By Treatment 14.4.1. Chemotherapy 14.4.2. Radiation Therapy 14.4.3. Steroid Therapy 14.4.4. Targeted Therapy 14.5. South America CNS Lymphoma Market Value Share Analysis, By Application 14.6. South America CNS Lymphoma Market Forecast, By Application 14.6.1. Hospitals 14.6.2. Clinics 14.6.3. Ambulatory Surgical Centers and Others 14.7. South America CNS Lymphoma Market Value Share Analysis, By Country 14.8. South America CNS Lymphoma Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America CNS Lymphoma Market Analysis, By Country 14.10. Brazil CNS Lymphoma Market Forecast, By Treatment 14.10.1. Chemotherapy 14.10.2. Radiation Therapy 14.10.3. Steroid Therapy 14.10.4. Targeted Therapy 14.11. Brazil CNS Lymphoma Market Forecast, By Application 14.11.1. Hospitals 14.11.2. Clinics 14.11.3. Ambulatory Surgical Centers and Others 14.12. Colombia CNS Lymphoma Market Forecast, By Treatment 14.12.1. Chemotherapy 14.12.2. Radiation Therapy 14.12.3. Steroid Therapy 14.12.4. Targeted Therapy 14.13. Colombia CNS Lymphoma Market Forecast, By Application 14.13.1. Hospitals 14.13.2. Clinics 14.13.3. Ambulatory Surgical Centers and Others 14.14. Argentina CNS Lymphoma Market Forecast, By Treatment 14.14.1. Chemotherapy 14.14.2. Radiation Therapy 14.14.3. Steroid Therapy 14.14.4. Targeted Therapy 14.15. Argentina CNS Lymphoma Market Forecast, By Application 14.15.1. Hospitals 14.15.2. Clinics 14.15.3. Ambulatory Surgical Centers and Others 14.16. Rest of South America CNS Lymphoma Market Forecast, By Treatment 14.16.1. Chemotherapy 14.16.2. Radiation Therapy 14.16.3. Steroid Therapy 14.16.4. Targeted Therapy 14.17. Rest of South America CNS Lymphoma Market Forecast, By Application 14.17.1. Hospitals 14.17.2. Clinics 14.17.3. Ambulatory Surgical Centers and Others 14.18. South America CNS Lymphoma Market Attractiveness Analysis 14.18.1. By Treatment 14.18.2. By Application 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Application, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Application 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Amgen 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Dr. Reddy’s Laboratories 15.3.3. Roche 15.3.4. Bristol-Myers Squibb 15.3.5. Cipla 15.3.6. Merck 15.3.7. Gilead Science 15.3.8. Novartis 15.3.9. AbbVie 15.3.10. Fresenius SE & Co 15.3.11. KGaA 15.3.12. Sanofi S.A 15.3.13. Celgene Corp 15.3.14. Johnson & Johnson 15.3.15. Others 16. Primary Key Insights

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample